A US district court in Delaware has scolded Galderma, telling the firm that it had “a theory but no proof,” as it firmly rejected the originator’s infringement claim against Lupin over two US patents shielding the Oracea (doxycycline) modified-release capsule treatment for rosacea.
‘Speculation Is Not Science’: Lupin Breezes Past Galderma On US Oracea Patents
Indian Firm Faces Immediate Appeal, After Originator Slammed By US District Court
Lupin received a more than favorable backing from a US district judge in Delaware, as the court shot down Galderma’s arguments that the Indian firm’s ANDA product would infringe two of its US Oracea patents.
More from Generics
• By
Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.
• By
The US FDA has deemed certain CRO Raptim Research’s in vitro bioequivalence studies as “not acceptable” and raised concerns over its in vivo study methods. Will other agencies follow suit?
• By
Teva should not be able to overturn European fines imposed over a historical “pay-for-delay” arrangement covering Cephalon’s Provigil (modafinil), an advocate general of the CJEU has recommended.
• By
Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.
More from Products
• By
Teva should not be able to overturn European fines imposed over a historical “pay-for-delay” arrangement covering Cephalon’s Provigil (modafinil), an advocate general of the CJEU has recommended.
• By
Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.
Gedeon Richter has filed its Mochida-partnered tocilizumab biosimilar rival to RoActemra with the European Medicines Agency. But with several biosimilars already having won approval, the market could be competitive.